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Abstract: Parkinson’s disease (PD) is the second most prevalent neurodegenerative disorder
worldwide. Clinically, it is characterized by severe motor complications caused by a progressive
degeneration of dopaminergic neurons (DAn) and dopamine loss. Current treatment is focused
on mitigating the symptoms through administration of levodopa, rather than on preventing DAn
damage. Therefore, the use and development of neuroprotective/disease-modifying strategies is
an absolute need, which can lead to promising gains on PD translational research. Mesenchymal
stem cells (MSCs)–derived exosomes have been proposed as a promising therapeutic tool, since it has
been demonstrated that they can act as biological nanoparticles with beneficial effects in different
pathological conditions, including PD. Thus, considering their potential protective action in lesioned
sites, MSCs-derived exosomes might also be active modulators of the neuroregeneration processes,
opening a door for their future use as therapeutical strategies in human clinical trials. Therefore, in
this review, we analyze the current understanding of MSCs-derived exosomes as a new possible
therapeutic strategy for PD, by providing an overview about the potential role of miRNAs in the
cellular and molecular basis of PD.
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1. Introduction
Described by James Parkinson in 1817, Parkinson’s disease (PD) is the second most common
chronic neurodegenerative disease in the world, affecting over 10 million people, and approximately 1%
of the world population over 60 years old [1]. Pathologically, PD is characterized by the degeneration of
dopaminergic neurons (DAn) and by the deficiency of dopamine production in several dopaminergic
networks. The loss of dopaminergic neurons is also linked with the formation/accumulation of Lewy
bodies (LB; protein aggregates of α-synuclein) in the intraneuronal structure, affecting the normal
functioning of those cells. From the networks impaired, the most affected one is the nigrostriatal
pathway at the level of the substantia nigra pars compacta (SNpc) and the striatum (STR) [2], initially
with an asymmetric onset that becomes bilateral as the disease progresses [3]. However, there are
other brain areas presenting the above referred hallmarks, such as the olfactory bulb, neocortex, limbic
system, and brainstem cells nuclei, suggesting a prion disease-like propagation and progression [4].
With this insight, a model was proposed, supporting LB transmission among cells as a possible route
for disease onset and progression. This model, called the Braak system, is divided in several stages, in
which the autonomic nervous system (ANS) is the first affected by the pathology (stage 0), followed by
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the dorsal motor nucleus of the vagus (DMV) and the anterior olfactory nucleus (stage 1), spreading to
the locus coeruleus (LC), SNpc, and basal forebrain (stage 2) and finally, to the neocortex, hippocampus,
and basal ganglia (final stages) [5]. As a result, when DAn death exceeds a threshold in the nigrostriatal
pathway it affects the patients’ motor system. Therefore, PD is clinically recognized by a core of motor
symptoms, including bradykinesia, rigidity, tremor, and postural instability, which are used in the
establishment of its diagnosis [6]. However, non-motor symptoms, such as depression, sleep disorders,
dementia, and peripheral impairments, have also been linked with functional disabilities, preceding
the appearance of the motor symptomatology [7]. Thus, the development of management strategies is
crucial, in which the diagnosis and the evaluation of the condition of the patient should be accurate,
being followed by the development and application of personalized strategies, aiming to ameliorate
the patient’s quality of life [8].
2. Molecular and Cellular Aspects of Parkinson’s Disease
As already mentioned, the major pathological feature of PD is the progressive loss of DAn in
the nigrostriatal system due to the presence of intraneuronal inclusions, namely LB [3]. Along with
SNpc’ DAn, other neural populations of the central (CNS) and peripheral nervous systems (PNS) are
affected by PD pathophysiology. For instance, in the PNS, the most affected subdivision is the ANS, in
which norepinephrine (NE) neurons innervating the heart and skin [9,10], as well as DAn of the enteric
nervous system (ENS) [11], are lost in PD. Actually, it is believed that the loss of these enteric DAn
leads to orthostatic hypotension, hyperhidrosis, and constipation, some of the less known symptoms
correlated with PD development. Regarding the CNS, almost all PD patients lose its neuromelanin
positive-catecholamine DAn at the levels of the SNpc and LC, something that is also observed in
DMV [12]. Still, DAn from the ventral tegmental area (VTA), retrorubal field (RRF), raphe nuclei (RN),
and basal nucleus of Meynert (BNM) are also lost in PD, but to a lesser extent [13]. Notwithstanding,
although several brain regions are claimed as being affected by PD pathophysiology, only the selective
loss of the SNpc’ DAn recognize the core symptoms of PD. Indeed, SNpc’ DAn are one of the longest
and most densely arborated neurons of the brain, projecting to the STR through a longer and thinner
unmyelinated axon [14]. In addition, studies have also suggest that as DAn axons make an elevated
number of synaptic connections, they appear to be more prone to damage [15], as it has been indicated
that the risk of local α-synuclein misfolding increases [16]. Furthermore, studies have also suggested
that SNpc DAn present a pacemaker activity that is regulated by specific Ca2+ channels, leading
to an increase in the cytosolic Ca2+ concentration [17]. Such an increase has been correlated with
the occurrence of cellular stress, leading to the formation of reactive oxygen species (ROS), which
are known to be detrimental to DAn viability [18]. The mitochondria is responsible for the DAn
calcium homeostasis, which in turn increases energy demand, contributing to the vulnerability of these
neurons [19]. In addition to this, dopamine itself could also be detrimental to DAn viability, as studies
have demonstrated that the increase of free cytosolic dopamine caused by an unbalanced homeostasis
at several levels (synthesis, storage, degradation, and/or distribution in the synaptic vesicles) favors
ROS production and oxidative stress, leading to DAn damage [20,21]. Moreover, the SNpc’ DAn
present a dark colored pigment, called neuromelanin (NM), which acts as a reservoir of iron, metals,
and other toxic substances, having a neuroprotective effect [22]. In addition to neuroprotection, NM has
recently been proposed as a promising biomarker for PD [23]. However, (DAn) dying neurons release
NM to the extracellular space, creating deposits that induce microglial activation, chemotaxis, and
proliferation, thus supporting SNpc inflammation and neuronal degeneration [24]. These multifactorial
features led to the study of the underlying mechanisms responsible for the loss of DAn linked to PD.
Rationally, the first question to be answered is how does PD begin at the cellular level? Although
this answer remains under discussion, several studies have demonstrated that the degeneration in
PD initiates in the synaptic and axonal terminals, beginning in the STR, and in a retrograde manner,
progresses to the SNpc’ DAn somas [25]. In fact, the literature shows that, at the time of the motor
symptoms onset, 30% of the SNpc’ DAn are lost, while 50–60% of the axon terminals in the STR
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are already degenerated [26]. However, the exact mechanisms of such degeneration is still not
understood and some concepts have been proposed throughout time. The most relevant mechanisms
involving PD include the disruption of protein clearance pathways, the accumulation of α-synuclein
protein aggregates, mitochondrial dysfunction, glutamate/calcium excitotoxicity, oxidative stress,
neuroinflammation, and genetic mutations [27]. Most of these mechanisms are related to DAn
sensitivity and susceptibility to degeneration, as previously described. However, cell death may be
caused by specific genetic mutations, which in turn affect several PD interlayers. Pathogenic mutations
in PD can lead to protein degradation systems’ (ubiquitin-proteasome and autophagy-lysosome
system) failure, which leads to the accumulation of misfolded α-synuclein, defective mitochondria,
thereby creating intercellular oxidative stress, and thus leading to DAn degeneration [28,29]. Although
it represents less than 10% of all PD cases, at least 17 autosomal dominant and autosomal recessive gene
mutations, namely, α-SYN (SNCA), PARKIN (PRKN), ubiquitin C-terminal hydrolase L1 (UCHL-1),
PTEN-induced putative kinase 1 (PINK1), protein deglycase (DJ-1, PARK7), and leucine-rich repeat
kinase 2 (LRRK2, PARK8) genes, among others have been identified [27]. Notwithstanding, although
most of the PD cases are sporadic (idiopathic), being caused by an interaction between genetic and
environmental factors [30], such as aging, inflammation, and exposure to neurotoxic agents (e.g.,
pesticides, such as rotenone and paraquat), both sporadic and familial forms of PD have mutual
molecular pathways, as shown in Table 1, making PD a multi-targeted disease in which new strategies,
with a multimodal action, may be of particular value [31].
Table 1. Sporadic and genetic types of Parkinson’s Disease (PD).
Sporadic PD
• Disruption of protein clearance pathways
• Accumulation of α-synuclein protein
• Mitochondrial dysfunction
• Excitotoxicity
• Oxidative stress
• Neuroinflammation
Genetic PD
SNCA Accumulation of α-synuclein protein aggregates.
PRKN Decrease in DJ-1 and PARKIN proteins, which leads to mitochondria dysfunction
when in oxidative stress conditions.PARK7
UCHL-1 No stabilization of ubiquitin monomers, which can lead toubiquitin-proteasome system dysfunction.
PINK1 Reduction in PTEN induced putative kinase 1 activity, which canlead to mitochondria malfunction.
PARK8 Overexpression of LRRK2 that causes DAn loss, accompanied by the presence of LB.
3. Parkinson’s Disease Treatments: Do We Have What Is Needed?
The loss of DAn and reduced dopamine production underlies the reasoning of the PD gold
standard treatment, which is still the administration of levodopa [32,33]. However, this strategy
remains insufficient to recover lost DAn, or to avoid PD progression, as its extended use, associated
with the needs of increased dosages, is linked with secondary effects, such as motor fluctuations and
behavioral changes (e.g., impulsivity and addiction) [34]. The field’s current view is that combinatory
strategies may overcome the limitations of single levodopa administration, particularly by combining
the latter with other PD pharmacological treatments. Such combined treatments have demonstrated
the ability to enhance and prolong levodopa efficacy by involving the use dopamine receptor agonists
(e.g., ropinirole, pramipexole, piribedil) [35]; inhibitors of peripheral enzymes, such as levodopa
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decarboxylase (e.g., carbidopa and benserazide) [36] or catechol-O-methyl transferase (COMT) (e.g.,
entacapone, tolcapone, and, more recently, opicapone) [37,38]; and inhibitors of central enzymes, such
as monoamine-oxidase B (MAO-B) (e.g., selegiline, rasagiline, or safinamide) [8,39] for oral intake.
Besides these, throughout the years, other options were developed without the direct application of
levodopa. This includes other dopamine agonists, such as rotigotine by transdermal application [40],
and apomorphine by subcutaneous administration [41]. Also, then N-methyl-D-aspartate (NMDA)
receptor antagonist (e.g., amantadine) was found to improve PD motor impairments, by reducing
dyskinesia and other PD-related complications [42]. Surgical procedures, such as deep brain
stimulation (DBS), have also been used in the treatment of PD, being a procedure that comprises
the delivery of electrical pulses to neurons through a neurostimulator implantation, either in the
subthalamic nucleus or in the internal part of the globus pallidus, leading to symptomatic relief [43].
In addition to these pharmacological and surgical treatments, in the last years, a large number of
new approaches have been developed to verify the effect of molecular agents (e.g., adenosine receptor
antagonists, anti-apoptotic agents, and antioxidants) and non-pharmacotherapies (e.g., viral vector
gene therapy, microRNAs, transglutaminases, and RTP801) in the treatment of PD [44]. However,
although promising results have been experimentally and clinically obtained with several drugs and
surgical experiments, yet the challenge remains to show a clinical proof of arrest of delay of DAn
loss in PD [8]. Therefore, there is an urgent need for the establishment of innovative therapies that
adequately target PD, particularly by inducing neuroprotection of the surviving DAn within the
SNpc-STR pathway, as well as stimulating the differentiation of new ones, so that the dopamine
balance can be re-established. With the advent of stem cell biotechnology, new routes are currently
being explored, particularly those aiming to protect DAn, as it is the case of human mesenchymal
stem cells (MSCs)-derived exosomes [45,46]. Therefore, in the scope of this review, we will discuss the
current understanding of MSCs-derived exosomes by reviewing recent experimental data addressing
the therapeutical potential of those vesicles in the context of PD.
4. Mesenchymal Stem Cells (MSCs)-Derived Exosomes and Parkinson’s Disease
MSCs-Derived Exosomes
As we have previously reviewed, according to the definition introduced by the International
Society for Cellular Therapy (ISCT), there are some minimal criteria for the identification of MSCs
populations, namely (1) the adherence to plastic in standard culture conditions; (2) the positive
expression of specific markers, like CD73, CD90, and CD105, and negative expression of hematopoietic
markers, like CD34, CD45, HLA-DR, and CD14, or CD11B, CD79α, or CD19; and (3) in vitro
differentiation into at least osteoblasts, adipocytes, and chondroblasts [47,48]. Therefore, MSCs
are a multipotent non-hematopoietic stem cell population that has emerged in the last decade as a
promising therapeutic tool for the treatment of several disorders, including PD [45,47]. This potential
is associated with their widespread availability throughout the human body, namely in the bone
marrow, adipose tissue, brain, dental pulp, placenta, umbilical cord blood, and Wharton’s jelly [47,49].
Notwithstanding, it is important to highlight that although all these populations are within the
definition of MSCs, they can have subtle differences, mainly in their membrane antigen markers [47].
Indeed, studies have demonstrated that such differences may be the result of different cell culture
protocols in their isolation and expansion or, alternatively, be related with the tissue source from
which they are being isolated [50,51]. Although, from the application point of view, studies have
shown that after (intracranial) transplantation, these cells act as promoters of immunomodulation,
neuroprotection, and neuronal differentiation [52,53]. These effects are essentially mediated by the
products that are released by MSCs into the extracellular milieu, commonly defined as secretome [54].
MSC-secretome has been described as a complex mixture of soluble products composed by a proteic
soluble fraction (constituted by growth factors and cytokines), and a vesicular fraction composed by
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microvesicles and exosomes, which are involved in the transference of proteins and genetic material
(e.g., miRNA) to other cells, with promising therapeutic effects [45,47].
Our lab has shown that MSC-secretome acts as an important promoter of neuroprotection,
neurodifferentiation, by modulating neural stem cells, neurons and glial cells, and axonal growth
in vitro and in vivo environments [52,55–61]. More recently, we have revealed that the use of dynamic
culturing conditions (through computer-controlled bioreactors) can further modulate MSC-secretome,
generating a more potent neurotrophic factor cocktail [62,63]. In the context of PD, we have recently
shown that its administration in the SNpc-STR pathway was able to partially revert the motor and
histological symptoms of a 6-OHDA PD rat model [64], indicating that MSC-secretome can be used as
a therapy for PD. Following on this work we have identified the presence of important neuroregulatory
molecules in the secretome of MSCs, including BDNF, IGF-1, VEGF, Pigment epithelium-derived factor
(PEDF), DJ-1, and Cystatin-C (Cys-C), that are being described as potential therapeutic mediators
against PD [62,65], as well as matrix metalloproteinases (MMPs), namely MMP 2, known for being
able to degrade alpha synuclein aggregates [65,66], and have correlated their presence with the impact
observed in our in vitro and in vivo models.
In addition to this protein fraction, the secretome also presents a vesicular portion, which is
composed by extracellular vesicles (EVs). The latter are important in cell-to-cell communication, as
they are involved in the transference of proteins and genetic material to neighboring cells [67]. EVs are
secreted by different cell types, such as neurons, microglia, epithelial, endothelial, and hematopoietic
cells, and stem cells as MSCs [68]. According to the International Society for Extracellular Vesicles
(ISEV), EVs are characterized by three minimal criteria: (1) Isolation from conditioned cell culture
medium or body fluids, with negligible cell disruption; (2) quantification of one protein (at least) from
three distinctive categories in the EV preparation-cytosolic proteins, transmembrane or lipid bound
extracellular proteins, and intracellular proteins; and (3) vesicles characterization using at least two
different technologies—by imaging (e.g., electron microscopy or atomic force microscopy) and EVs
size distribution measurements (e.g., nanoparticle-tracking analysis or resistive pulse sensing) [69].
EVs are classified as microvesicles, exosomes, and apoptotic cell bodies [70] based on their size, origin,
and cargo. Regarding their size, exosomes are the smallest type, being classified as vesicles with a
range of 30-150 nm, while microvesicles and apoptotic bodies have a 50–1000 nm and 50–2000 nm
diameter, respectively [71]. EVs are distinguished as exosomes if formed inside multivesicular bodies
(MVBs) at the endolysosomal pathway and secreted upon MVBs fusion with the membrane, in contrast
to microvesicles, which form from the sprouting of the plasma membrane, while apoptotic bodies
originate from dying cells fragments [72]. Exosomes are the best characterized EV population and
were first discovered in 1983 in maturing sheep retilocytes [73]. Exosomes present a phospholipid layer
characterized by sphingolipids, ceramides, tetraspanins (CD63, CD9, CD81), fusion proteins (flotillins,
CD9, annexin), integrins, heat shock proteins (HSC70 and HSC90), membrane transporters (GTPases),
lysosomal proteins (Lamp2b), tumor sensitive gene (TSG101), and Alix [74]. Regarding their cargo,
exosomes contain a variety of biomolecules, such as cell-type specific proteins, signaling peptides,
lipids, and genetic material (e.g., miRNA, small RNA, genomic DNA, mRNA, long non-coding RNA,
tRNA, cDNA, and mtDNA), which once released to the extracellular environment, are taken up by
other cells [75]. This interaction can lead to changes in the cell phenotype or to a modulation of the
cell activity, raising the question of whether exosomes can represent the basis for the creation of new
therapeutical strategies under the (CNS) regenerative medicine field. Indeed, studies have remarkably
explored and demonstrated exosomes as a delivery system of therapeutical signals or drugs due to their
low immunogenicity, ability to cross the blood-brain barrier (BBB), and long half-life in circulation [76].
As described, different cell types secrete exosomes, however, in this review, we highlight the ones
derived from the secretome of MSCs, since they show promising effects by triggering regenerative
responses in different pathological conditions. MSC-derived exosomes were firstly isolated and
described in 2010 from human MSCs-derived from embryonic stem cells (ESC) [77]. Actually, since
their discovery, an increasing number of studies explored their regenerative potential using diverse
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in vitro and in vivo models of several pathological conditions by demonstrating that the uptake of
MSCs-derived exosomes are able to stimulate angiogenesis and myogenesis, promote functional and
morphologic rescue due to a decrease of oxidative stress and suppression of apoptosis, as well as the
modulation of inflammatory responses [78–83].
Concerning CNS pathologies, MSCs-derived exosomes have also shown therapeutical benefits.
For instance, in stroke, intravenous administration of MSCs-derived exosomes induced an increase
of neurogenesis, neurite remodeling, and angiogenesis, facts that were correlated with a substantial
improvement of animals’ functional recovery [84]. Such a tendency was also observed in a traumatic
brain injury model, showing an inflammation reduction and good outcomes after MSCs-derived
exosomes’ administration [85]. The injection of MSCs-derived exosomes has also been shown to
be a possible treatment for spinal cord injury (SCI), by reducing inflammation and by promoting
neuro-regeneration in rats after injury [86,87]. In neurodegenerative diseases, such as Alzheimer’s,
studies have shown MSCs-derived exosomes expressing high levels of the amyloid β-degrading
enzyme, neprilysin (NEP), leading to a decrease of brain Aβ levels [88], and thus having an impact on
the disease progression. In the context of PD, MSCs-derived exosomes were found to rescue DAn in
in vitro (6-OHDA) models of PD, providing a potential regenerative treatment for this disorder [89].
However, although promising results have been claimed by MSCs-derived exosomes, studies
have also claimed that the exosomes content depends on the tissues where MSCs are originally isolated
and the environment in which they are present, setting the need to further study the different functional
exosomal properties. Such an assumption is in line with previous results published by our group,
which demonstrated that MSCs from different sources have different secretome profiles, thereby
indicating that such a difference in their secretion pattern may indicate that their secretome or derived
vesicles may be specific to a condition of the CNS [65].
5. Exosomal Genetic Material Content: Are miRNAs Important in the Modulation of the
Molecular and Cellular Issues of PD?
As previously mentioned, one of the most common content of exosomes is the presence
of genetic material, such as microRNAs (miRNAs) [90]. Actually, it has been indicated that
numerous diseases, including PD, exhibit intense dysregulation of gene expression, specifically
at the miRNA level [91]—Figure 1. In addition to its involvement in PD pathophysiology,
exosome-derived microRNAs have also been identified as a potential tool for diagnosis biomarkers
and targeted therapies.
miRNAs are the most studied class of non-coding RNAs (ncRNA), with between 21–25 nt, and
are responsible for the regulation of specific genes through RNA messenger (mRNA) degradation or
inhibition of their translation [92]. Still, miRNAs bind to the untranslated region (UTR) of the mRNA
target and recruit the RNA induced silencing complex (RISC) in order to inhibit the expression of
these targets, therefore, regulating specific gene expression, and presenting key roles in normal cellular
physiology [93]. In animals, miRNAs are produced in two stages, starting from primary miRNAs
(pri-miRNAs), and by the action of Drosha/DGCR8 RNase in the nucleus, and Dicer RNase in the cell
cytoplasm [94]. This miRNA biogenesis pathway is of great importance and is essential for normal
development since Dicer knockout (KO) mice are not able to survive beyond the embryonic stage [95].
Also, it was shown that impairments in Dicer in mice midbrain leads to a progressive loss of DAn [96],
and post-mortem brain analysis showed DAn loss combined with LB, when the DGCR8 gene was
deleted (chromosome 22q11.2 deletion syndrome) [97].
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Several miRNA-mediated dysfunction networks in PD-related genes have recently been reported.
Concerning the SNCA gene, several miRNAs have been suggested as α-synuclein modulators. For
instance, interference in the binding between miR-433 and fibroblast growth factor 20 (FGF20) mRNA
leads to increased levels of FGF20, which in turn also increases the levels of the α-synuclein protein
in the cell [98]. Moreover, an abnormal increase of the miR-16-1 levels inhibits to a greater extent
the translation of the HSP70 mRNA (protein that inhibits α-synuclein), which in turn also leads to
an increase of the α-synuclein protein levels [99]. Also, PD-related pathogenic processes blocking
miR-7, miR-153, and miR-34b/c from binding on their α-synuclein mRNA target automatically leads
to increased levels of α-synuclein [100–102]. Regarding PRKN and PARK7 genes, they express,
respectively, the PARKIN and DJ-1 proteins, which present important roles in the normal cell
functioning and PD. PARKIN protein partakes in the proteasome-mediated degradation, and it is
expressed in the mitochondria, where it binds to mtDNA, protecting it against damage promoted
by oxidative stress conditions [103]. DJ-1 protein is considered an oxidative detector and it binds to
PARKIN protein in oxidative stress conditions, protecting the mitochondria from oxidative stress [104].
Also, mutations in the PARK7 gene make DAn more susceptible to ROS-mediated damage [105]. In
PD, a correlation was found between the decrease of miR-34b/c levels and the consequent decrease
of the PARKIN and DJ-1 proteins in several brain areas [106]. Also, an upregulation of miR-494 and
miR-4639-5p causes a direct reduction of DJ-1 protein expression, making DAn more vulnerable and
prone to the PD phenotype [107,108]. Moreover, LRRK2 gene (PARK8) mutations cause sporadic PD
associated to a neuropathology characterized by SNpc’ DAn loss, which is, in some cases, accompanied
by the formation and presence of LB [109]. In fact, studies verified an increase of LRRK2 expression
in PD patients when compared with controls, correlating this increase with a downregulation of
miR-205 [110]. Another miRNA associated with the dopaminergic phenotype in PD is miR-133b,
which is found to be downregulated in PD patients, and it regulates the transcriptional activator, Pitx3,
an important factor in DAn development [111]. Additionally, other miRNAs were found to regulate
the expression of genes involved in neuroinflammation, an important hallmark of PD. In this context,
studies have found that miR-155 plays a key role in the upregulation of the inflammatory response to
α-synuclein fibrils. This occurs by the fact that miR-155 is a modulator of proinflammatory molecules,
such as IL-1, IL-6, TNF-α, and iNOS, leading to its upregulation [112]. Also, an miR-155 KO mice
model showed that the lack of this miRNA prevented reactive microgliosis, as well as the loss of
DAn triggered by the overexpression of α-synuclein [113]. In the same line of thought, miR-7, which
was previously reported as an important factor in the regulation of α-synuclein levels, has also been
presented as an important player in the modulation of neuroinflammation. For instance, the injection
of miR-7 in the STR of an MPTP mouse model of PD was found to block NLRP3 inflammasome
activation, leading to a remarkable attenuation of DAn death [114].
In addition to this involvement in PD pathophysiology, miRNAs are also being investigated
as a potential source of PD biomarkers, in which the exosomes are being identified as a great
use for diagnosis and prognosis of the disease. Indeed, Vizoso and colleagues [115] have recently
proposed that MSCs-derived secretome is sufficient to significantly improve multiple biomarkers of the
pathophysiology, making it a potential strategy to be used for the establishment and identification of
promising PD biomarkers. As we have previously described, MSCs are able to secrete large quantities
of exosomes carrying miRNAs, and such miRNAs may function not only as a novel class of promising
biomarkers, but as modulators of multiple systems that could play critical roles in several diseases,
including PD. Therefore, the possibility of using it as a potential therapeutic strategy for the treatment
of PD is starting to emerge. To target the brain areas affected in PD, miRNAs must be delivered into
the brain through a transport system able to cross the BBB—Figure 2. Due to the multi-faceted nature
of exosomes, its application in clinics is something that could be envisaged in the near future [116].
However, firstly, some challenges need to be addressed, namely: (1) The correct (MSC) cell line;
(2) exploration of the most efficient and reliable yield isolation technique associated to an efficient
scalable production; (3) development of robust loading methods without damage to the exosomal
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integrity, in order to ensure an improved insight into PD cellular and molecular mechanisms, and
finally to (4) address and plan possible strategies to improve (MSCs) exosomes’ targeting capability.
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MSCs-derived exosomes may constitute a new key solution. Indeed, several studies show
that MSCs-derived exosomes are able to transfer miRNAs to neuronal cells, in which exosomes
enriched in miR-133b can promote neurite outgrowth [117], which is of great benefit for PD, as it
is one of the miRNAs that is normally downregulated in the disease. Still, miR-143 and miR-21
were also found to be present in MSCs-derived exosomes, being described as important players in
immune response modulation and in neuronal death associated with an environment of chronic
inflammation [118]. Similarly, an miRNA cluster is also present in MSCs-derived exosomes, being
formed by miR-17, miR-18a, miR-19a/b, miR-20a, and miR-90a, and being described as important
modulators of neurite remodeling and neurogenesis, as well as stimulators of axonal growth and
CNS recovery [119]. For instance, mimics, such as mimic-miR-124, are able to promote subventricular
zone (SVZ) neurogenesis, which was shown after intracerebral administration in a 6-OHDA mice
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model of PD, and was also correlated with significant behavioral improvements [120]. In contrast, the
mimic-miR-7 is also able to suppress NLRP3 and α-synuclein in the nigrostriatal pathway, thereby
providing a potential therapeutic effect for PD. Regarding the antago-miRs, the antago-miR-155 may be
relevant to PD therapy, since miR-155 plays a key role in the microglial cells activation in PD, leading
to neuroinflammation. Finally, the overexpression of miR-126 leads to an impairment in the IGF-1
signaling, increasing DAn vulnerability to the PD neurotoxin, 6-OHDA. Notwithstanding, when using
an antago-miR-126, the opposite occurs, resulting in neuroprotective effects induced by IGF-1 [121].
In summary, the development of an understanding of the molecular mechanisms regulated by
miRNAs and the potential of MSCs-derived exosomes in how they impact PD brain homeostasis may
allow the creation and development of important clinical gains to be translated to PD patients.
6. Conclusions and Future Perspectives
PD is a severe neurodegenerative disease that affects millions of people worldwide, and despite
the advances in the PD research field, the molecular and cellular basis underlying this disease are still
not fully understood. While important gains were achieved with the current pharmacological/surgical
treatments in the quality of life of PD patients, they have failed to arrest PD progression and do not
promote DAn protection/differentiation. Thus, a new approach that allows an understanding of
the cellular and molecular mechanisms of PD to identify new therapeutical strategies and targets
is necessary. Currently, MSC-secretome has been proposed as a promising therapeutic tool for
several neurodegenerative diseases, like PD, given their ability to modulate DAn survival. Within it,
MSCs-derived exosomes constitute, along with the protein fraction, an important tool and therapeutic
option. Indeed, the exchange of genetic material, such as miRNA, through exosomes can promote
neurogenesis, reduce neuroinflammation, as well as promote functional recovery in animal models.
In fact, miRNAs have gained an important status in the PD research field not only due to its
involvement in PD pathogenesis, but also as an opportune window to use as biomarkers or as potential
therapeutic agents for PD treatment. Therefore, understanding the complexity of MSCs-derived
exosomes, and how its miRNA content interacts with the molecular and cellular PD mechanisms is
of great importance. Such an approach will not only allow the exploitation of potential pathways
involved in the recovery/compensation mechanisms of the disease, but also in the development
of multi-target-based strategies that could generate potential clinical benefits to be translated for
PD patients.
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